Skip to main content

Advertisement

SpringerLink
Log in

The potential role of perlecan domain V as novel therapy in vascular dementia

  • Review Article
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

Vascular dementia (VaD) is the second most common cause of dementia and leads to a decline in cognitive thinking via conditions that lead to blockage or reduced blood flow to the brain. It is a poorly understood disease, and the changes that occur are often linked to other types of dementia such as Alzheimer’s disease. To date, there are no approved therapies or drugs to treat the symptoms of VaD, even though there is some evidence of drugs approved for Alzheimer’s that might have some benefit in patients diagnosed with VaD. The altered blood flow that precedes VaD may result in compensatory mechanisms, such as angiogenesis, to increase blood flow in the brain. Angiogenesis, the process of new blood vessel formations from pre-existing ones, involves several pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and is regulated by a variety of growth factors from neurons, astrocytes, and pericytes in the brain as well the extracellular matrix (ECM). The ECM highly regulates angiogenesis and other processes in the brain. One such ECM component is the heparan sulfate proteoglycan perlecan and its bioactive region, Domain V (DV). Here we discuss the potential role of DV as a novel therapy to treat VaD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Arikawa-Hirasawa E et al (1999) Perlecan is essential for cartilage and cephalic development. Nat Genet 23:354–358

    Article  CAS  PubMed  Google Scholar 

  • Bix G et al (2004) Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin. J Cell Biol 166(1):97–109

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bix G et al (2013) Perlecan domain V is neuroprotective and affords functional improvement in a photothrombotic stroke model in young and aged mice. Transl Stroke Res 5(5):515–23

    Article  Google Scholar 

  • Caplan L, Gomes J (2010) Binswanger disease—an update. J Neurol Sci 299:9–10

    Article  PubMed  Google Scholar 

  • Clarke D et al (2012) Perlecan domain v induces VEGF secretion in brain endothelial cells through integrin α5β1 and ERK-dependent signaling pathways. PLoS One 7(9):e45257

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Costell M et al (1999) Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 147(5):1109–1122

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Farach-Carson M, Carson D (2007) Perlecan: a multifunctional extracellular proteoglycan scaffold. Glycobiology 17(9):897–905

  • Ferrer I (2010) Cognitive impairment of vascular origin: Neuropathology of cognitive impairment of vascular origin. J Neurol Sci 299:139–149

    Article  PubMed  Google Scholar 

  • Fujita Y et al (2010) Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke 41(12):2938–43

    Article  PubMed  Google Scholar 

  • Fukuda S et al (2004) Focal cerebral ischemia induces active proteinases that degrade microvascular matrix. Stroke 35(4):998–1004

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ghiso J et al (2010) Cerebral amyloid angiopathy and Alzheimer’s disease. Hirosaki Igaku 61:S111–124

    CAS  PubMed Central  PubMed  Google Scholar 

  • Goyal A et al (2011) Endorepellin, the angiostatin module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): A dual receptor antagonism. J Biol Chem 286(29):25947–62

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Harris J et al (2000) Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. PNAS 97(14):7754–59

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hooijmans C et al (2012) The effects of long-term omega-3 fatty acid supplementation of cognition and Alzheimer’s pathology in animals models of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 28(1):191–209

    CAS  PubMed  Google Scholar 

  • Iadecola C et al (2009) Threats to the mind: aging, amyloid, and hypertension. Stroke 40(3):S40–4

    Article  PubMed Central  PubMed  Google Scholar 

  • Iemolo F, et al (2009) Pathophysiology of vascular dementia. Immunity and Aging 6(13)

  • Iozzo R, San Antonio J (2001) Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 108(3):349–355

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Jellinger K (2013) Pathology and pathogenesis of vascular cognitive impairment—a critical update. Front Aging Neurosci 5:17

    Article  PubMed Central  PubMed  Google Scholar 

  • Jiang X et al (2004) Essential contribution of tumor-derived perlecan to epidermal tumor growth and angiogenesis. J Histochem Cytochem 52(12):1575–90

  • Kahle P et al (2012) Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue. Neuroreport 23(10):627–30

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kravitz E et al (2012) Cognitive decline and dementia in the oldest-old. Rambam Maimonides Med J 3(4):e0026

    Article  PubMed Central  PubMed  Google Scholar 

  • Lee B et al (2011) Perlecan domain v is neuroprotective and proangiogenic following ischemic stroke in rodents. J Clin Invest 121(8):3005–23

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lin B (2013) Encephalopathy: a vicious cascade following forebrain ischemia and hypoxia. Cent Nerv Syst Agents Med Chem 13:57–70

    Article  PubMed  Google Scholar 

  • Maki T et al (2011) Angiogenic roles of adrenomedullin through vascular endothelial growth factor induction. Neuroreport 22(9):442–7

    Article  CAS  PubMed  Google Scholar 

  • Milner R et al (2008) Increased expression of fibronectin and the α5β1 integrin in angiogenic cerebral blood vessels of mice subject to hypobaric hypoxia. Mol Cell Neurosci 38(1):43–52

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mongiat M et al (2003) Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278(6):4238–49

    Article  CAS  PubMed  Google Scholar 

  • Parham C et al (2014) Perlecan domain v inhibits amyloid-beta induced brain endothelial cell toxicity and restores angiogenic function. J Alzheimers Dis 38(2):415–23

    CAS  PubMed Central  PubMed  Google Scholar 

  • Roberts J et al (2012) Perlecan and the blood-brain barrier: beneficial proteolysis? Front Pharmacol 3:155

  • Rocca W, Kokmen E (1999) Frequency and distribution of vascular dementia. Alzheimer Dis Assoc Disord 13(3):S9–14

    PubMed  Google Scholar 

  • Rodgers K et al (2007) Reduced perlecan in mice results in chondrodysplasia resembling Schwartz-Jampel syndrome. Hum Mol Genet 16(5):515–28

    Article  CAS  PubMed  Google Scholar 

  • Saini M, Bix G (2012) Oxygen-glucose deprivation (OGD) and interleukin-1 (IL-differentially modulate cathepsin B/L mediated generation of neuroprotective perlecan LG3 by neurons. Brain Res 1438:65–74

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Shee W, Ong W, Lim T (1998) Distribution of perlecan in mouse hippocampus following intracerebroventricular kainite injections. Brain Res 799(2):292–300

    Article  CAS  PubMed  Google Scholar 

  • Shibata M et al (2004) White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke 35(11):2598–603

    Article  PubMed  Google Scholar 

  • Thal D et al (2012) Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol 47(11):816–24

    Article  PubMed Central  PubMed  Google Scholar 

  • Van Horssen J et al (2001) Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer’s disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol 102(6):604–16

    Article  PubMed  Google Scholar 

  • Viswanathan A, Chabriat H (2006) Cerebral microhemorrhage. Stroke 37(2):550–5

    Article  PubMed  Google Scholar 

  • Whitelock J et al (1996) The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271(17):10079–86

    Article  CAS  PubMed  Google Scholar 

  • Wiesmann M et al (2013) Vascular aspects of cognitive impairment and dementia. J Cereb Blood Flow Metab 33(11):1696–706

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Willis C et al (2013) Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells. FEBS J 280(10):2271–84

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Wright S et al (2012) Perlecan domain V inhibits α2 integin-mediated amyloid-β neurotoxicity. Neurobiol Aging 33(7):1379–88

    Article  CAS  PubMed  Google Scholar 

  • Yamada K et al (2010) Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease. Brain Res 1352:176–86

    Article  CAS  PubMed  Google Scholar 

  • Zhao G et al (2003) Temporal profile of tissue plasminogen activator (tPA) and inhibitor expression after transient focal cerebral ischemia. Neuroreport 14(13):1689–92

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Dr. Jill Roberts and Leon de Hoog for their helpful comments on this manuscript.

Author information

Authors and Affiliations

  1. Sanders-Brown Center on Aging, Department of Anatomy and Neurobiology and Department of Neurology, University of Kentucky, 430 Sanders Brown Building, 800 S. Limestone Street, Lexington, KY, 40536-0230, USA

    Aileen Marcelo & Gregory Bix

Authors
  1. Aileen Marcelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory Bix
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory Bix.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marcelo, A., Bix, G. The potential role of perlecan domain V as novel therapy in vascular dementia. Metab Brain Dis 30, 1–5 (2015). https://doi.org/10.1007/s11011-014-9576-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-014-9576-6

Keywords

Search

Navigation